MedXY News - DPP‑4 inhibitors

Clinical UpdatesDPP‑4 inhibitorsGLP-1 receptor agonists

Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study

By MedXY|Jul 5, 2026

Postoperative GLP-1RA initiation after liver resection for hepatocellular carcinoma in type 2 diabetes patients is associated with improved recurrence-free and overall survival compared to DPP-4 inhibitors, indicating potential incremental

DPP‑4 inhibitors

Latest news

Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study

GLP-1 Receptor Agonists Show Lower Heart Failure Risk Versus DPP-4 Inhibitors in Type 2 Diabetes

Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes

Beyond Glycemic Control: Empagliflozin/Linagliptin Combination Restores Urinary Microbiota Homeostasis in Type 2 Diabetes

SGLT2 Inhibitors Linked to Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes